Jay Lalezari, CEO, CytoDyn, emphasizes how regulatory T cells play a crucial role in tumor progression by enabling cancers to ...

Artificial intelligence is a wildcard in the selection process, most profoundly in its agentic form. AI agents 2 will help ...

Novo Nordisk’s board overhaul signals a decisive return to Foundation-led scientific and operational governance, raising strategic questions about whether the company can sustain U.S. growth and ...

Stanton’s research, including the 2023 HBS case “Generative AI and the Future of Work,” underscores a pivotal truth: AI will not eliminate jobs en masse in the near term, but it will reshape them, ...

Olympia Pharmaceuticals expanded into Mississippi, now licensed in 49 states, enhancing access to compounded pharmaceuticals and manufacturing capabilities. The company's strategy emphasizes ...

PE: How do global pharma growth strategies differ from domestic strategies? Ackerman: There are two different models for ...

Dr. Jaspal Singh explains some of the barriers that prevent cancer patients from getting biomarker testing early in their ...

In today’s Pharmaceutical Executive Daily, WeightWatchers plans to offer Novo Nordisk’s oral Wegovy pending FDA approval, FDA unveils a new Plausible Mechanism Pathway to accelerate drug reviews, and ...

Merck's acquisition of Cidara Therapeutics for $9.2 billion focuses on CD388, a promising antiviral for influenza prevention.

The FDA has granted full approval to Kura Oncology and Kyowa Kirin’s Komzifti (ziftomenib), marking the first FDA-approved once-daily, oral menin inhibitor for adults with relapsed or refractory (R/R) ...

Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, discusses how events from the past ...

Jay Lalezari, CEO of CytoDyn, explains how the CCR5 receptor has emerged as a pivotal target in metastatic cancers due to its ...